Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1615-1615
Open Access | Times Cited: 10

Showing 10 citing articles:

Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation
Richard J. Mead, Ning Shan, H. Joseph Reiser, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 3, pp. 185-212
Open Access | Times Cited: 256
New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs)
Chella Perumal Palanisamy, Jinjin Pei, Phaniendra Alugoju, et al.
Theranostics (2023) Vol. 13, Iss. 12, pp. 4138-4165
Open Access | Times Cited: 66
Frontotemporal dementia. How to deal with its diagnostic complexity?
Annibale Antonioni, Emanuela Maria Raho, Enrico Granieri, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access | Times Cited: 2
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients
Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld, et al.
Clinical and Translational Science (2022) Vol. 15, Iss. 8, pp. 2010-2023
Open Access | Times Cited: 51
Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future
Leonard A. Levin, Christopher Patrick, Nozhat Choudry, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 25
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian Fiske, et al.
Nature Reviews Drug Discovery (2025)
Closed Access
Advancing precision medicine therapeutics for Parkinson’s utilizing a shared quantitative systems pharmacology model and framework
Christopher Denaro, Diane Stephenson, Martijn L.T.M. Müller, et al.
Frontiers in Systems Biology (2024) Vol. 4
Open Access | Times Cited: 3
A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
Maurits F. J. M. Vissers, Matthew D. Troyer, Eva Thijssen, et al.
Clinical and Translational Science (2023) Vol. 16, Iss. 8, pp. 1408-1420
Open Access | Times Cited: 5
Pain Research and Treatment: Policy Implications
Maral Tajerian, Sebastian Alvarado
Policy Insights from the Behavioral and Brain Sciences (2024) Vol. 11, Iss. 1, pp. 110-117
Closed Access
Future Advances in Early Phase Clinical Development for Disease Modifying Therapies for Neurodegenerative Diseases
Philip Kremer, Geert Jan Groeneveld
Medical Research Archives (2022) Vol. 10, Iss. 9
Open Access
Page 1

Scroll to top